Tandem Diabetes Care (NASDAQ:TNDM) Raised to "Outperform" at Leerink Partnrs

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) was upgraded by equities researchers at Leerink Partnrs from a "market perform" rating to an "outperform" rating in a research note issued to investors on Thursday, Zacks.com reports.

A number of other equities research analysts have also recently commented on TNDM. StockNews.com upgraded shares of Tandem Diabetes Care from a "sell" rating to a "hold" rating in a research note on Friday, April 19th. Citigroup lifted their price objective on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a "neutral" rating in a research report on Wednesday, April 3rd. Stifel Nicolaus lifted their price objective on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, SVB Leerink upgraded shares of Tandem Diabetes Care from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $34.00 to $45.00 in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $39.45.

Tandem Diabetes Care Stock Performance

NASDAQ TNDM traded down $0.32 on Thursday, reaching $35.24. 783,779 shares of the stock were exchanged, compared to its average volume of 1,721,603. Tandem Diabetes Care has a one year low of $13.82 and a one year high of $40.74. The firm has a market capitalization of $2.28 billion, a PE ratio of -10.24 and a beta of 1.12. The company's 50-day simple moving average is $30.74 and its two-hundred day simple moving average is $25.26. The company has a current ratio of 3.83, a quick ratio of 3.02 and a debt-to-equity ratio of 0.91.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. The firm had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Analysts expect that Tandem Diabetes Care will post -1.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. MCF Advisors LLC boosted its stake in Tandem Diabetes Care by 79.3% during the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company's stock worth $36,000 after buying an additional 445 shares during the period. Van ECK Associates Corp boosted its stake in Tandem Diabetes Care by 8.6% during the fourth quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company's stock worth $175,000 after buying an additional 467 shares during the period. Diversified Trust Co boosted its stake in Tandem Diabetes Care by 5.6% during the fourth quarter. Diversified Trust Co now owns 10,573 shares of the medical device company's stock worth $313,000 after buying an additional 564 shares during the period. Raymond James & Associates boosted its stake in shares of Tandem Diabetes Care by 1.9% during the third quarter. Raymond James & Associates now owns 40,264 shares of the medical device company's stock valued at $836,000 after purchasing an additional 737 shares during the period. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Tandem Diabetes Care by 10.1% during the third quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company's stock valued at $205,000 after purchasing an additional 908 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.